NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 907.2 DKK | -0.30% |
|
+3.09% | +30.34% |
| 04:34pm | Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal | MT |
| 02:08pm | NOVO NORDISK : JP Morgan reaffirms its Buy rating | ZD |
| Sales 2024 * | 289B 41.98B 3,336B | Sales 2025 * | 349B 50.64B 4,025B | Capitalization | 4,053B 588B 46,720B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.1B 1,200B | Net income 2025 * | 127B 18.36B 1,460B | EV / Sales 2024 * | 14 x |
| Net Debt 2024 * | 13.34B 1.93B 154B | Net cash position 2025 * | 12.63B 1.83B 146B | EV / Sales 2025 * | 11.6 x |
| P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
32.1
x | Employees | 66,015 |
| Yield 2024 * |
1.3% | Yield 2025 * |
1.56% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
| 1 day | -0.38% | ||
| 1 week | +3.22% | ||
| Current month | +0.93% | ||
| 1 month | +3.62% | ||
| 3 months | +7.57% | ||
| 6 months | +33.42% | ||
| Current year | +30.50% |
1 week
881.60
927.00
1 month
826.70927.00
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.94% | ||
| 10.45% | 5 M€ | +12.31% | ||
| 5.40% | 17 M€ | +6.46% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 909.7 | -0.02% | 1 857 217 |
| 13/05/24 | 909.9 | +3.02% | 4,150,455 |
| 08/05/24 | 883.2 | +0.07% | 2,737,492 |
| 07/05/24 | 882.6 | +3.66% | 9,320,634 |
Delayed Quote Nasdaq Copenhagen, May 14, 2024 at 03:31 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
909.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.34% | 586B | |
| +29.30% | 682B | |
| -3.23% | 364B | |
| +17.69% | 327B | |
| +3.67% | 285B | |
| +16.17% | 240B | |
| +10.02% | 209B | |
| -8.55% | 203B | |
| +7.79% | 165B | |
| -1.30% | 161B |
- Stock Market
- Equities
- NOVO B Stock
